About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Regeneron (NASDAQ: REGN) is testing its drug, trevogrumab, along with Wegovy and another treatment, garetosmab, in a ...
Doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures ...
Wegovy and Zepbound target the GLP-1 protein to help control appetite. Veru was first with results in January from a 168-person trial, showing its enobosarm helped older patients lose 71% less ...
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Veru's oral drug, enobosarm, targets the androgen hormones that play a role in body development and reproductive health. In a mid-stage study, patients who received the drug along with Wegovy lost ...
The dozen new drugs, including those furthest along in development from Eli Lilly, Regeneron, Scholar Rock and Veru, target proteins tied to muscle preservation or growth. Wegovy and Zepbound ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback